Actualités

Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.

While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.

Acquisition could strengthen its neuroscience growth strategy

The deal gives Lilly a late-stage psychedelic treatment for hard-to-treat depression.

Lilly will pay $6.75 a share in cash, plus up to $1 billion in milestones

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.

Eli Lilly (LLY) could see further momentum from positive amylin and tirzepatide data supporting its

Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.

Novo Nordisk is relying on first-mover advantage in the obesity pill arena to close the gap on Eli Lilly.

PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.

AtaiBeckley (ATAI) shares surged more than 30% on Thursday after Eli Lilly (LLY) said it agreed to a

This acquisition marks Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline.

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

AtaiBeckley stock surges after a Bloomberg report said Eli Lilly is in talks for a potential acquisition of the company, as investors await details of the deal.

Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.

Eli Lilly announced it is buying AtaiBeckley in a bet on neuroscience and psychiatric pharmaceuticals.

While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.

While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression...

FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Eli Lilly and Novo Nordisk.

(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus

Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting sentiment across the space.

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s recent buying spree.

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing a recent buying spree. Eli will pay $6.75 a share in cash for the biopharma company, a 26% premium to yesterday's closing price of $5.

The deal gives Lilly access to a DMT-based nasal spray for treatment-resistant depression that has received FDA Breakthrough Therapy Designation

The radiopharma specialist will use earnings from this mega-round to progress ADVC001 and build manufacturing infrastructure to prepare for potential commercialisation.

GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences (NASDAQ:ATAI), a development that sparked renewed investor interest across the sector. Potential acquisition lifts sentiment across psychedelic drug developersThe reported takeover talks sent Atai shares soaring by as much as 53% before the opening bell, with investors speculating that increased pha

AtaiBeckley (NASDAQ:ATAI) shares jumped as much as 53% in premarket trading on Thursday after reports emerged that Eli Lilly (NYSE:LLY) is in discussions to acquire the psychedelic drug developer. Potential deal would broaden Lilly’s neuroscience portfolioAccording to BMO Capital Markets analyst Evan David Seigerman, an acquisition of AtaiBeckley would strengthen Eli Lilly’s presence in psychiatry while supporting its strategy of expanding beyond its established cardiometabolic business.

Psychedelic drugmaker AtaiBeckley was surging 50% ahead of the open Thursday following a report that pharma giant Eli Lilly is nearing a deal to buy the company . A deal, being negotiated at a premium, could be announced as early as this week, Bloomberg reported, citing people familiar with the matter. The shares jumped 22% in a single day in April when President Donald Trump signed a directive to accelerate the Food and Drug Administration’s review of psychedelic drugs for serious mental illnesses.